Home / Market News / $ABT
benzinga Corporate Catalyst Impact 85/100 ● negative

Abbott Laboratories shares are trading lower after the company reported Q3 financial results and narrowed its FY26 adjusted EPS guidance. The company announced it will spin off its nutrition business into an independent publicly traded company.

Oct 21, 2026, 11:56 AM UTC · Primary ticker $ABT

Abbott Laboratories' shares are down due to a mixed Q3 report and a narrowed FY26 EPS guidance, indicating potential near-term headwinds. The announced spin-off of its nutrition business introduces significant structural changes that could unlock value but also create short-term uncertainty.

The headline presents a significant corporate catalyst for Abbott Laboratories (ABT). The immediate negative reaction is driven by the narrowed FY26 EPS guidance, suggesting a less optimistic outlook than previously anticipated. However, the spin-off of the nutrition business is a major strategic move that could unlock shareholder value by allowing both entities to focus on their core competencies. This creates a 'sum-of-the-parts' valuation opportunity but also introduces execution risk and potential for short-term volatility as investors digest the implications of the separation. The healthcare sector, particularly diversified medical device and diagnostics companies, will be watching closely for the success of this strategic realignment.

$ABT negative Lower guidance, spin-off uncertainty
$MDLZ neutral Potential competitor in nutrition
$PG neutral Potential competitor in nutrition
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.